{"id":3093,"date":"2026-04-10T08:29:03","date_gmt":"2026-04-10T05:29:03","guid":{"rendered":"https:\/\/merkezlaboratuvari.com\/test-listesi\/ca-19-9-2\/"},"modified":"2026-04-21T12:38:41","modified_gmt":"2026-04-21T09:38:41","slug":"ca-19-9","status":"publish","type":"page","link":"https:\/\/merkezlaboratuvari.com\/ar\/test-listesi\/ca-19-9\/","title":{"rendered":"CA 19-9"},"content":{"rendered":"<h1>CA 19-9<\/h1>\n<h2>Laboratuvar Bilgileri<\/h2>\n<ul>\n<li><strong>Yeni Kod:<\/strong> BIO5508<\/li>\n<li><strong>SUT Kodu:<\/strong> L101940<\/li>\n<li><strong>Eski Kod:<\/strong> HR0020<\/li>\n<li><strong>Kategori:<\/strong> \u0643\u064a\u0645\u064a\u0627\u0621 \u062d\u064a\u0648\u064a\u0629<\/li>\n<li><strong>Numune T\u00fcr\u00fc:<\/strong> Serum<\/li>\n<li><strong>Numune Kab\u0131:<\/strong> Sar\u0131 Kapak<\/li>\n<li><strong>\u00c7al\u0131\u015fma G\u00fcn\u00fc:<\/strong> Her g\u00fcn<\/li>\n<li><strong>\u00d6nemli Kriter:<\/strong> \u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r.<\/li>\n<li><strong>Raporlama Tarihi:<\/strong> Ertesi g\u00fcn 18:00<\/li>\n<\/ul>\n<h2>CA 19-9 Testi Nedir?<\/h2>\n<p>CA 19-9, laboratuvar ortam\u0131nda de\u011ferlendirilen bir biyokimya testidir. De\u011ferlendirme \u00e7o\u011fu zaman serum \u00f6rne\u011fi \u00fczerinden planlan\u0131r.<\/p>\n<p>CA 19-9 (Cancer Antigen 19-9), Lewis kan grubu antijenine ba\u011fl\u0131 bir karbonhidrat antijenidir. Ba\u015fl\u0131ca pankreas kanseri ile ili\u015fkilendirilir ve pankreatobiliyer sistem malignitelerinin tan\u0131, takip ve tedavi yan\u0131t\u0131 de\u011ferlendirmesinde en s\u0131k kullan\u0131lan t\u00fcm\u00f6r belirtecidir. Safra yolu kanserleri ve di\u011fer gastrointestinal kanserlerde de y\u00fckselebilir.<\/p>\n<p>Bu testin klinik anlam\u0131; istem nedeni, hastan\u0131n yak\u0131nmalar\u0131, ya\u015f\u0131, e\u015flik eden hastal\u0131klar\u0131, kullan\u0131lan y\u00f6ntem ve di\u011fer laboratuvar bulgular\u0131 ile birlikte de\u011ferlendirilir. Bu nedenle sonu\u00e7, tek ba\u015f\u0131na de\u011fil, b\u00fct\u00fcnc\u00fcl t\u0131bbi \u00e7er\u00e7eve i\u00e7inde yorumlanmal\u0131d\u0131r.<\/p>\n<h2>CA 19-9 Hangi Durumlarda \u0130stenir?<\/h2>\n<p>CA 19-9 testi, hekim taraf\u0131ndan klinik gereklilik g\u00f6r\u00fclen durumlarda istenebilir. \u0130stem gerek\u00e7esi hastan\u0131n mevcut tablosuna g\u00f6re de\u011fi\u015febilir.<\/p>\n<ul>\n<li>Pankreas kanseri \u015f\u00fcphesi ve takibi<\/li>\n<li>Pankreas kanseri tedavi yan\u0131t\u0131n\u0131n izlenmesi<\/li>\n<li>Safra yolu kanserleri (kolanjiokarsinoma) tan\u0131 ve takibi<\/li>\n<li>Safra kesesi kanseri takibi<\/li>\n<li>Cerrahi sonras\u0131 n\u00fcks takibi<\/li>\n<li>Pankreatik kitle ay\u0131r\u0131c\u0131 tan\u0131s\u0131 (benign-malign ayr\u0131m\u0131)<\/li>\n<\/ul>\n<p>Ayn\u0131 test farkl\u0131 hastalarda farkl\u0131 klinik sorulara yan\u0131t aramak amac\u0131yla kullan\u0131labildi\u011fi i\u00e7in, nihai de\u011ferlendirme her zaman ki\u015fisel t\u0131bbi \u00f6yk\u00fc ve muayene bulgular\u0131 ile birlikte yap\u0131lmal\u0131d\u0131r.<\/p>\n<h2>CA 19-9 Testi \u00d6ncesi Haz\u0131rl\u0131k<\/h2>\n<p>Haz\u0131rl\u0131k gereksinimi; testin t\u00fcr\u00fcne, numune yap\u0131s\u0131na ve laboratuvar\u0131n \u00e7al\u0131\u015fma kurallar\u0131na g\u00f6re de\u011fi\u015febilir. Test \u00f6ncesinde laboratuvar\u0131n ve hekimin verdi\u011fi talimatlar esas al\u0131nmal\u0131d\u0131r.<\/p>\n<ul>\n<li>\u00d6zel bir haz\u0131rl\u0131k gerekmez.<\/li>\n<li>A\u00e7l\u0131k \u015fart\u0131 genellikle istenmez.<\/li>\n<li>Obstr\u00fcktif sar\u0131l\u0131k durumunda de\u011ferlerin yanl\u0131\u015f y\u00fcksek olabilece\u011fi bilinmelidir.<\/li>\n<li>Kullan\u0131lan ila\u00e7lar hakk\u0131nda hekime bilgi verilmelidir.<\/li>\n<\/ul>\n<p>Kullan\u0131lan ila\u00e7lar, takviyeler, yak\u0131n d\u00f6nemde ge\u00e7irilen hastal\u0131klar ve e\u015flik eden kronik durumlar sonucun yorumlanmas\u0131n\u0131 etkileyebilece\u011fi i\u00e7in sa\u011fl\u0131k profesyoneli ile payla\u015f\u0131lmal\u0131d\u0131r.<\/p>\n<h2>CA 19-9 Testi Nas\u0131l Yap\u0131l\u0131r?<\/h2>\n<p>CA 19-9 testi, uygun biyolojik \u00f6rnek al\u0131nd\u0131ktan sonra laboratuvar\u0131n belirledi\u011fi y\u00f6ntemle \u00e7al\u0131\u015f\u0131l\u0131r. Numunenin do\u011fru zamanda, uygun kapta ve uygun ta\u015f\u0131ma ko\u015fullar\u0131nda ula\u015ft\u0131r\u0131lmas\u0131 test kalitesi a\u00e7\u0131s\u0131ndan \u00f6nem ta\u015f\u0131r.<\/p>\n<ul>\n<li><strong>Numune T\u00fcr\u00fc:<\/strong> Serum<\/li>\n<li><strong>Numune Kab\u0131:<\/strong> Sar\u0131 Kapak<\/li>\n<li><strong>\u00c7al\u0131\u015fma G\u00fcn\u00fc:<\/strong> Her g\u00fcn<\/li>\n<li><strong>\u00d6nemli Kriter:<\/strong> \u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r.<\/li>\n<li><strong>Raporlama Tarihi:<\/strong> Ertesi g\u00fcn 18:00<\/li>\n<\/ul>\n<ul>\n<li>Koldan ven\u00f6z kan \u00f6rne\u011fi al\u0131n\u0131r (serum t\u00fcp\u00fcne).<\/li>\n<li>\u0130\u015flem birka\u00e7 dakika s\u00fcrer.<\/li>\n<li>Sonu\u00e7lar genellikle ayn\u0131 g\u00fcn veya ertesi g\u00fcn \u00e7\u0131kar.<\/li>\n<\/ul>\n<p>Baz\u0131 durumlarda \u00f6rnek kalitesi, numune miktar\u0131, ta\u015f\u0131ma s\u00fcresi veya teknik tekrar gereksinimi raporlama s\u00fcresini ve sonucun g\u00fcvenilirli\u011fini etkileyebilir.<\/p>\n<h2>CA 19-9 Testi Ka\u00e7 G\u00fcnde \u00c7\u0131kar?<\/h2>\n<p>Mevcut laboratuvar bilgisine g\u00f6re bu test i\u00e7in raporlama s\u00fcresi: <strong>Ertesi g\u00fcn 18:00<\/strong> \u015feklindedir.<\/p>\n<p>Numunenin kabul zaman\u0131, laboratuvar\u0131n \u00e7al\u0131\u015fma plan\u0131, resmi tatiller veya gerekti\u011finde tekrar \u00e7al\u0131\u015fma gibi etkenler sonucu etkileyebilece\u011fi i\u00e7in en g\u00fcncel bilgi rapor tarihi \u00fczerinden de\u011ferlendirilmelidir.<\/p>\n<h2>Referans De\u011ferleri ve Sonu\u00e7lar\u0131n De\u011ferlendirilmesi<\/h2>\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Grup<\/th><th>De\u011fer<\/th><\/tr><\/thead><tbody><tr><td>Yeti\u015fkinler<\/td><td>0 \u2013 37 U\/mL<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<p>> Not: Lewis antijeni negatif bireylerde (toplumun yakla\u015f\u0131k %5-10&#8217;u) CA 19-9 \u00fcretilemez ve t\u00fcm\u00f6r varl\u0131\u011f\u0131nda bile de\u011fer d\u00fc\u015f\u00fck kal\u0131r. Referans de\u011ferleri laboratuvara g\u00f6re farkl\u0131l\u0131k g\u00f6sterebilir.<\/p>\n<p>Referans bilgileri; kullan\u0131lan y\u00f6ntem, ya\u015f grubu, biyolojik \u00f6rnek tipi ve laboratuvar standard\u0131na g\u00f6re de\u011fi\u015febilece\u011finden, rapor \u00fczerinde yer alan laboratuvar yorumu esas al\u0131nmal\u0131d\u0131r.<\/p>\n<h2>CA 19-9 Sonucu Nas\u0131l Yorumlan\u0131r?<\/h2>\n<p>Test sonucu tek ba\u015f\u0131na kesin tan\u0131 koydurmaz. Sonu\u00e7; klinik bulgular, di\u011fer laboratuvar verileri ve gerekli g\u00f6r\u00fcld\u00fc\u011f\u00fcnde ek incelemeler ile birlikte de\u011ferlendirilir.<\/p>\n<h3>Y\u00fcksek CA 19-9 D\u00fczeyleri<\/h3>\n<p><strong>Malign nedenler:<\/strong><\/p>\n<ul>\n<li>Pankreas kanseri (hastalar\u0131n %70-90&#8217;\u0131nda y\u00fckselir)<\/li>\n<li>Kolanjiokarsinoma (safra yolu kanseri)<\/li>\n<li>Safra kesesi kanseri<\/li>\n<li>Mide kanseri<\/li>\n<li>Kolorektal kanser<\/li>\n<li>Over kanseri (m\u00fcsin\u00f6z tip)<\/li>\n<li>Karaci\u011fer kanseri<\/li>\n<\/ul>\n<p><strong>Benign nedenler:<\/strong><\/p>\n<ul>\n<li>Obstr\u00fcktif sar\u0131l\u0131k (safra yolu t\u0131kan\u0131kl\u0131\u011f\u0131)<\/li>\n<li>Akut ve kronik pankreatit<\/li>\n<li>Safra ta\u015flar\u0131, kolanjit<\/li>\n<li>Karaci\u011fer sirozu, hepatit<\/li>\n<li>Kistik fibrozis<\/li>\n<li>\u0130nflamatuvar ba\u011f\u0131rsak hastal\u0131klar\u0131<\/li>\n<li>Tiroid hastal\u0131klar\u0131<\/li>\n<li>Diyabetes mellitus<\/li>\n<\/ul>\n<h3>Takipte CA 19-9 De\u011fi\u015fimleri<\/h3>\n<ul>\n<li><strong>Cerrahi sonras\u0131 d\u00fc\u015f\u00fc\u015f:<\/strong> Ba\u015far\u0131l\u0131 rezeksiyonu g\u00f6sterir.<\/li>\n<li><strong>Cerrahi sonras\u0131 y\u00fcksek kalmas\u0131:<\/strong> Rezid\u00fcel t\u00fcm\u00f6r veya gizli metastaz d\u00fc\u015f\u00fcnd\u00fcr\u00fcr.<\/li>\n<li><strong>Kemoterapi alt\u0131nda d\u00fc\u015f\u00fc\u015f:<\/strong> Tedaviye yan\u0131t\u0131 g\u00f6sterir.<\/li>\n<li><strong>Yeniden y\u00fckselme:<\/strong> N\u00fcks a\u00e7\u0131s\u0131ndan uyar\u0131c\u0131d\u0131r.<\/li>\n<li><strong>\u00c7ok y\u00fcksek de\u011ferler (>1000 U\/mL):<\/strong> \u0130noperabl hastal\u0131k ile ili\u015fkilidir.<\/li>\n<\/ul>\n<h3>\u00d6nemli Notlar<\/h3>\n<ul>\n<li>CA 19-9 tarama testi olarak kullan\u0131lmaz.<\/li>\n<li>Lewis antijeni negatif bireylerde CA 19-9 \u00fcretilemez; bu ki\u015filerde test yan\u0131lt\u0131c\u0131 olarak d\u00fc\u015f\u00fck kal\u0131r.<\/li>\n<li>Obstr\u00fcktif sar\u0131l\u0131kta CA 19-9 belirgin \u015fekilde y\u00fckselebilir; sar\u0131l\u0131k d\u00fczeldikten sonra tekrar de\u011ferlendirilmelidir.<\/li>\n<li>Tek bir de\u011fer yerine seri \u00f6l\u00e7\u00fcmlerle takip daha anlaml\u0131d\u0131r.<\/li>\n<li>Preoperatif y\u00fcksek CA 19-9 k\u00f6t\u00fc prognozla ili\u015fkilidir.<\/li>\n<\/ul>\n<p>\u00d6zellikle s\u0131n\u0131rda, d\u00fc\u015f\u00fck d\u00fczeyli veya beklenmeyen sonu\u00e7larda klinik korelasyon gerekir. Gerekti\u011finde tekrar test, panel de\u011ferlendirmesi veya ek laboratuvar incelemeleri planlanabilir.<\/p>\n<h2>Testin S\u0131n\u0131rl\u0131l\u0131klar\u0131<\/h2>\n<p>Her laboratuvar testinde oldu\u011fu gibi bu incelemenin de baz\u0131 s\u0131n\u0131rl\u0131l\u0131klar\u0131 vard\u0131r. Sonu\u00e7; \u00f6rnek kalitesi, \u00f6rnekleme zaman\u0131, ta\u015f\u0131ma ko\u015fullar\u0131 ve klinik ba\u011flamdan etkilenebilir.<\/p>\n<ul>\n<li>Tek bir laboratuvar sonucu, klinik \u00e7er\u00e7eve d\u0131\u015f\u0131nda eksik yorumlanabilir.<\/li>\n<li>Uygun olmayan numune kalitesi sonucun g\u00fcvenilirli\u011fini azaltabilir.<\/li>\n<li>Gerekti\u011finde ek testler olmadan tek ba\u015f\u0131na karar vermek yan\u0131lt\u0131c\u0131 olabilir.<\/li>\n<\/ul>\n<h2>Olas\u0131 Riskler<\/h2>\n<p>Risk \u00e7o\u011funlukla numune alma ve numune y\u00f6netimi s\u00fcreci ile ili\u015fkilidir. Testin kendisinden \u00e7ok, \u00f6rne\u011fin al\u0131nmas\u0131 ve uygun ko\u015fullarda \u00e7al\u0131\u015f\u0131lmas\u0131 \u00f6nem ta\u015f\u0131r.<\/p>\n<ul>\n<li>Kan al\u0131m\u0131na ba\u011fl\u0131 hafif a\u011fr\u0131, morarma veya \u015fi\u015flik olabilir.<\/li>\n<li>Nadiren enfeksiyon veya a\u015f\u0131r\u0131 kanama g\u00f6r\u00fclebilir.<\/li>\n<li>Testin kendisine ba\u011fl\u0131 ciddi bir risk yoktur.<\/li>\n<li><strong>Yanl\u0131\u015f pozitif:<\/strong> Obstr\u00fcktif sar\u0131l\u0131k ve pankreatit gibi benign durumlarda belirgin y\u00fckseklik g\u00f6r\u00fclebilir.<\/li>\n<li><strong>Yanl\u0131\u015f negatif:<\/strong> Lewis antijeni negatif bireylerde kanser varl\u0131\u011f\u0131nda bile d\u00fc\u015f\u00fck kalabilir.<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>CA 19-9 Laboratuvar Bilgileri Yeni Kod: BIO5508 SUT Kodu: L101940 Eski Kod: HR0020 Kategori: Biyokimya Numune T\u00fcr\u00fc: Serum Numune Kab\u0131: Sar\u0131 Kapak \u00c7al\u0131\u015fma G\u00fcn\u00fc: Her g\u00fcn \u00d6nemli Kriter: \u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r. Raporlama Tarihi: Ertesi g\u00fcn 18:00 CA 19-9 Testi Nedir? CA 19-9, laboratuvar ortam\u0131nda de\u011ferlendirilen bir [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":0,"parent":5,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"test_category":"Biyokimya","test_kodu":"BIO5508","numune_turu":"Serum","numune_kabi":"Sar\u0131 Kapak","calisma_gunu":"Her g\u00fcn","onemli_kriter":"\u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r.","raporlama_tarihi":"Ertesi g\u00fcn 18:00","numune_red_kriterleri":"","aktarim_kodu":"","loinc_kodu":"","sut_kodu":"L101940","akredite":"","numune_miktari":"","alternatif_ornek":"","numune_alinma_sekli":"","stabilite_ozellikleri":"","calisma_yontemi":"","test_bilgisi":"","footnotes":""},"class_list":["post-3093","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/3093","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/types\/page"}],"replies":[{"embeddable":true,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/comments?post=3093"}],"version-history":[{"count":5,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/3093\/revisions"}],"predecessor-version":[{"id":8956,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/3093\/revisions\/8956"}],"up":[{"embeddable":true,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/5"}],"wp:attachment":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/media?parent=3093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}